Palantir's Revenue Soared at "an Otherwordly Growth Rate" of 63% in Q3. Here's Why That Isn't Enough.

Palantir Technologies (PLTR) reported robust Q3 results, with revenue surging 63% to $1.18 billion and adjusted EPS of $0.21, both surpassing analyst estimates. Despite this strong performance, the stock saw a modest decline in after-hours trading, primarily due to its extreme valuation, which CEO Alex Karp described as a "nosebleed zone." With a forward P/E of 217 and P/S of 137, significantly above S&P 500 and industry averages, the article highlights that even Palantir's impressive growth may not be enough to justify its current premium, especially given potentially slowing Q4 guidance.

Analysis

Palantir Technologies (PLTR) reported robust Q3 2025 results, with revenue surging 63% year-over-year to $1.18 billion and adjusted EPS reaching $0.21, both significantly surpassing Wall Street's consensus estimates of $1.09 billion and $0.17, respectively. This performance marked an acceleration from Q2's 48% revenue growth. Despite these strong beats, PLTR shares experienced an approximate 2% decline in after-hours trading, indicating investor focus beyond immediate financial performance.

The primary driver for the muted market reaction is Palantir's extreme valuation, which CEO Alex Karp himself described as a "nosebleed zone." The stock trades at a forward price-to-earnings ratio of 217 and a trailing price-to-sales ratio of 137, metrics that are substantially higher than any other S&P 500 company and 15.6 times the average application software P/S multiple of 8.8. This premium valuation suggests that even exceptional growth may not be sufficient to justify current price levels.

Management's Q4 2025 guidance projects a slight deceleration in revenue growth at the upper end of the range, potentially exacerbated by impacts from a U.S. federal government shutdown. While Palantir's business fundamentals and product offerings are strong, the article emphasizes that current growth rates, even at 63%, are insufficient to support its current market capitalization. The overall sentiment towards PLTR is moderately negative, reflecting caution regarding its valuation.

Key Decisions for Investors

• Investors should critically re-evaluate existing Palantir (PLTR) positions given the extreme valuation metrics and the CEO's own 'nosebleed zone' assessment.
• Monitor Q4 2025 guidance and actual results closely for any deceleration in revenue growth or impacts from the U.S. federal government shutdown.
• Exercise caution when considering new investments in PLTR, as even robust growth may not justify its substantial premium compared to S&P 500 and industry averages.